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Introduction. Chronic inflammatory response is one of major contributors in the development of hepatocellular carcinoma (HCC).
Inflammatory molecules, such as cytokines and growth factors in the circulation, can be useful in the diagnosis and prognosis of
the patients. The stem cell growth factor beta (SCGF𝛽), a newly found protein, is a secreted sulfated glycoprotein and it functions
as a growth factor for primitive hematopoietic progenitor cells. The level of SCGF𝛽 had been reported to be elevated in several
cancer types. However, there is very few or even no information on this protein in the study of HCC, even more in clinical
studies. Methods. A multiplex immunoassay panel of 48 cytokines and growth factors were utilized to screen 68 sera from 29
HCC patients at pretreatment (T0), 1 month (T1), and 6 months (T6) after treatment by either radiofrequency ablation (RF) or
transarterial chemoembolization (TACE). Treatment responsewas evaluated according tomRECIST criteria.Results. Immunoassay
screening showed that the levels of IL-17, CTACK, TNF𝛼, IL-2R𝛼, IL-8, and SCGF𝛽 were different in Complete Responders (CR)
and Nonresponders (NR) groups. At T0 and T1, the SCGF𝛽 level was significantly the highest in NR (23.8 and 40.7 ng/mL,
respectively), followed by early recurrence (25.4 and 25.0 ng/mL), and CR (6.7 and 5.3 ng/mL), independently from HCV, stages,
and treatment type. Low basal SCGF𝛽 level was associated with longer disease-free survival compared to high SCGF𝛽. Conclusion.
In this study, for the first time, we demonstrate that the high level of serum SCGF𝛽 at pre- and posttreatment is associated with
HCC nonresponsiveness.
1. Introduction
Liver cancer is one of the most common cancers, being the
second cause of cancer related death worldwide.The progno-
sis of this cancer is poor and the geographical patterns in inci-
dence andmortality are similar [1]. Hepatocellular carcinoma
(HCC) accounts for about 90% of liver cancer cases, with
cirrhosis as the strongest underlying condition [2]. Interna-
tional guideline recommends image-guided radiofrequency
(RF) ablation as the treatment of choice forHCCpatientswith
early-stage HCC when liver transplantation or hepatectomy
is precluded. For patients in intermediate stage, palliative
treatment by using transarterial chemoembolization (TACE)
is recommended [3].However, in spite of growing technology
advances in the cancer diagnosis and treatment techniques,
the long-term survival of the patients is still inadequate
because of the high rates of cancer recurrence [4].
It is known that chronic inflammatory response is a
main risk factor for HCC progression [5], deriving both
from viral and metabolic etiological factors of the disease.
Inflammatory molecules, such as cytokines and trophic
growth factors, can be useful in the diagnosis and prognosis
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of the patients. Different serum biomarkers can be used to
predict the prognosis of patients with unresectable HCC [6–
8], in patients who received RF and TACE therapy [9–11],
and in patients with advanced stages treated with Sorafenib
[12, 13]. However, only few studies have shown the use of
serumbiomarkers to predict an early recurrence of the cancer
and the patients’ response. Furthermore, due to the diversity
of stimulated cytokines, most of the reported studies used a
rather homogeneous group receiving a similar therapy.
The stem cell growth factor (SCGF) is a protein encoded
by geneCLEC11A, amember of the C-type lectin superfamily.
SCGF is a secreted sulfated glycoprotein and functions as a
growth factor for primitive hematopoietic progenitor cells.
SCGF is expressed in two distinct forms; SCGF𝛼 is the full
size form (35 kDa), while SCGF𝛽 is the shorter form (27 kDa)
characterized by a deletion within a conserved carbohydrate
recognition domain. In primary breast cancer, the level of
SCGF𝛽 was elevated in the circulating tumor cells (CTC) in
mononuclear cells of peripheral blood [14]. In lung cancer,
drug-resistant cancer stem cells- (CSC-) derived tumors with
marker CD133+ contained two- to threefold higher levels of
human angiogenic and growth factors, including the SCGF𝛽
[15]. However, there is very few or even no information on
this protein on the study of HCC, even more in HCC patients
treated with RF and TACE.
This study reports on the screening of 48 cytokines and
trophic factors involved in cancer development in predicting
the response of the patients in both early and intermediate
stages of HCC receiving RF and TACE.We show that SCGF𝛽
level can be used to predict HCC recurrence after either RF
or TACE.
2. Materials and Methods
2.1. Patient Selection and Classification. Patients referring to
the Liver Center eligible for the assigned treatment protocols
of TACE and RF were recruited in the study. The diagnosis of
HCC was formulated based on standard radiologic findings
by computerized tomography and magnetic resonance imag-
ing scan when the typical imaging features were present [3].
Based on the HCC recurrence, patients were classified
into two main groups: patients without any HCC recurrence
at 6 months after treatment (T6) were defined as Complete
Responders (CR, n=13), while Nonresponders (NR, n=16)
were the patients with HCC recurrence within 6 months.
The NR group was then subclassified into a group with
HCCappearance/persistency in the firstmonth (unsuccessful
therapy; NRT1, n=5) and another groupwithHCC recurrence
between 1 and 6 months (NRT6, N=11). Patients were further
defined according to gender, age, previous treatment (TACE,
RF, and liver resection); etiology (hepatitis C virus (HCV),
hepatitis B virus (HBV), alcohol, and metabolic); laboratory
finding (levels of alpha fetoprotein (AFP), alanine amino-
transferase (ALT), and aspartate aminotransferase (AST));
and disease score (BarcelonaClinic Liver Cancer (BCLC) and
Child Pugh Turcotte (CPT)).
Written informed consent was obtained from patient or
by a legal representative and patient anonymity has been
preserved. Investigation was conducted according to the
principles expressed in the Declaration of Helsinki. The
regional ethical committee (Comitato Etico Regionale Unico
of the Friuli Venezia Giulia, Prot. No. 18854) approved the
study.
2.2. Quantification of Serum Cytokines. Sera were collected
on the day just before treatment (T0), at 1 month (T1) and 6
months (T6) after treatment. Samples were stored at -80∘C
until quantification. In brief, 50 𝜇L of serum and standard
was added in a 96-multiwell plate containing analyte beads
(Bio-Plex, BIO-RAD Laboratories, Milan, Italy) based on a
magnetic beadmultiplex immunoassays. After incubation for
30 minutes at room temperature and washing, the antibody-
biotin reporter was added and incubated for 10 minutes
with streptavidin-phycoerythrin. The concentrations of the
cytokines were determined using the Bio-Plex array reader
(Luminex, Austin, TX). The Bio-Plex Manager software
optimized the standard curves automatically and returned
the data asMedian Fluorescence Intensity (MFI) and concen-
tration (pg/ml).This assay has a reported limit of detection of
1–20 pg/ml, depending on the cytokine target. Each sample
was run in a blind fashion, and the value of all individual data
was collected for the analysis.
The screening was carried out for complete panel of 48
cytokines, chemokines, and trophic factors (21-plex and 27-
plex BioRad). Cytokines analyzed were IL-1𝛼, IL-2Ra, IL-
3, IL-12p40, IL-16, IL-18, IFN- 𝛼2, LIF, MIF, SCF, TNF-
𝛽, TRAIL/TNFSF10, IL-1𝛽, IL-1Ra, IL-2, IL-4, IL-5, IL-
6, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17, IFN-𝛾, and
TNF-𝛼. Chemokines analyzed were CTACK/CCL27, GRO𝛼/
CXCL1, MCP-3/CCL7, MIG/CXCL9, SDF-1𝛼/CXCL12, IL-
8/CXCL8, Eotaxin/CCL11, MCP-1/CCL2, MIP-1𝛼/CCL3, IP-
10/CXCL10, MIP-1𝛽/CCL4, and RANTES/CCL5. Trophic
factors analyzed were HGF, M-CSF, 𝛽-NGF, SCGF-𝛽, IL-
7, FGF basic, G-CSF, PDGF-b, VEGF, and GM-CSF. All of
mentioned factors had been reported to have important roles
in cancer development, progression, or metastasis.
2.3. Survival Analysis. Recurrence and survival were defined
as the time elapsed between treatment of HCC and the first
detection of HCC reappearance and death, respectively. For
analysis, recurrence and survival of patients with low and
high level of serum SCGF𝛽 were compared using Kaplan-
Meier curves and the log-rank test. Cutoff value was defined
by a Receiver Operating Characteristic (ROC) curve plotting
the true positive rate (sensitivity) against false positive rate
(100 - specificity).
2.4. Statistical Analysis. The values of serum cytokines were
mentioned as median (min-max). Statistical comparison
between groups was performed using software InStat Version
3.05 (GraphPad Software, Inc., La Jolla, CA, USA) and IBM
SPSS statistics program version 24 (IBM Corporation, New
York, USA). Statistical significance was set to p<0.05.
3. Results
3.1. Basal Cytokine Concentration. The complete clinical and
pathological characteristics of the patients enrolled in the
study are listed in Table 1. A total of 68 sera samples from
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Table 1: Clinical-pathological characteristics of the patients enrolled in the study.
RF TACE TOTAL p
Patients characteristics
Male / Female 11/4 11/3 22/7 ns
Age 72 ± 5 68 ± 10 70 ± 8 0.010
Etiologies 15 14 29 ns
Alcohol/metabolic 9 7 16
Alcohol 1 3 4
HCV 5 4 9
Clinical characteristics
CTP A/B 10/0 15/4 25/4 0.042
BCLC 0/A/B 2/10/3 2/5/7 4/15/10 ns
Milan criteria (in/out) 13/1 8/3 21/4 (unknown 4) ns
Up-to-7 criteria (in/out) 14/0 9/2 23/2 (unknown 4) ns
Largest nodule diameter (mm) 29 ± 10 27 ± 7 28 ± 9 ns
Total tumor volume (cm3) 18 ± 24 22 ± 25 20 ± 24 ns
Laboratory finding
Creatinine (mg/dl) 0.9 ± 0.3 0.8 ± 0.2 0.9 ± 0.2 ns
Sodium (mmol/l) 136.0 ± 2.2 138.4 ± 2.6 138.0 ± 2.4 ns
Total bilirubin (mg/dl) 0.94 ± 0.33 1.33 ± 0.93 1.12 ± 0.68 0.033
Total protein (g/dl) 7.2 ± 0.5 7.4 ± 0.7 7.2 ± 0.6 ns
Albumin (g/dl) 3.8 ± 0.4 3.6 ± 0.3 3.7 ± 0.3 ns
AST (IU/l) 77.7 ± 79.7 46.7 ± 24.3 63.9 ± 62.5 0.001
ALT (IU/l) 80.3 ± 96.7 37.4 ± 19.4 61.2 ± 75.3 0.001
ALP (IU/l) 101.3 ± 44.1 101.8 ± 40.7 101.5 ± 41.8 ns
GGT (IU/l) 112.4 ± 109 135.3 ± 146.5 123.4 ± 126.7 ns
WBC (103/𝜇l) 5.1 ± 2.1 4.8 ± 2.1 4.97 ± 2.07 ns
Hemoglobin (g/dl) 13.5 ± 2.1 13.7 ± 1.5 13.6 ± 1.8 ns
Hematocrit (%) 40.4 ± 5.7 40.6 ± 4.3 40.5 ± 4.9 ns
Platelets (103/𝜇l) 135.7 ± 80 102.6 ± 55.3 119.7 ± 70.2 ns
AFP (ng/ml) 20 ± 30.7 18.5 ± 23.3 19.3 ± 26.8 ns
INR 1.12 ± 0.1 1.18 ± 0.1 1.14 ± 0.12 ns
HCV: hepatitis C virus, CTP: Child-Turcotte-Pugh, BCLC: Barcelona Clinic Liver Cancer, AST: aspartate aminotransferase, ALT: alanine aminotransferase,
ALP: alkaline phosphatase, GGT: gamma glutamyl transferase, WBC: white blood cells, AFP: alpha fetoprotein, INR: international normalized ratio, and ns:
not significant
29 HCC patients were recruited with prevalence of gender
M22/F7 with a mean age of 70 years (min 53, max 83), 9 with
HCV infection, and 20 with alcohol or metabolic etiologies.
RF ablation and TACE were performed in 15 patients and 14
patients, respectively. HCC score wasmainly CPT score A (29
patients) and BCLCA and B (17 and 10 patients, respectively).
The mean of basal AFP and ALT level was 17.8 ± 24.1 ng/mL
and 48.0 ± 45.5 U/L, respectively.
By using a screening of 48 cytokines and growth factors
in a Luminex platform, our data on the differential cytokines
with the basal clinical and pathological parameters is shown
in Table 2. We observed that, in HCV-related HCC, the levels
of IP-10, IL-2R𝛼, and MIG were significantly increased, with
the IP-10 level showing the highest difference for around 3-
fold (median value 950 [398 – 2586] and 2606 [1478 – 7454],
for HCV- and HCV+ HCC, respectively) (p<0.001). As for
HCC staging, the level of serum IL-8 was found to be around
two-times higher in BCLC B (25.4 [10.3 – 53.9]) compared
to BCLC A group (11.9 [2.3 – 23.9]) (p<0.05)]. As for the
treatment group, we found that significant difference between
group TACE and RF was noticed only for IL-15 and SDF-1a
(p<0.01).
3.2. Serum SCGF𝛽 Level to Predict HCCRecurrence. To study
the correlation between the level of cytokines/growth factors
and HCC recurrence, we compared the CR and NR groups
at pretreatment (T0) and at 1 month after treatment (T1). We
found various cytokines and growth factors to be differently
expressed in CR compared to NR patients group. Several
factors such as IL-17, CTACK, and TNF𝛼 were increased in
CR patients, while IL-2R𝛼, IL-8, and SCGF𝛽 were higher in
NR patients. Among these differentiated factors, we found
that the SCGF𝛽 could distinguish the CR andNR groupswith
a high significant value (p<0.01) (Figure 1).
We performed further analysis by subclassifying the NR
group into two groups of patients based on early or later
HCC recurrence, asmentioned inMaterials andMethods.We
found that both at T0 and T1, the level of SCGF𝛽was found to
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Table 2: Basal levels of circulating cytokines in HCC patients.
Cytokine level (pg/ml) [median (min-max)]
Viral infection HCV+ (n=10) HCV- (n=19) p
IP-10 2606 (1478 – 7454) 950 (398 – 2568) <0.001
IL-2R𝛼 117 (58 – 284) 65 (1 – 182) <0.05
MIG 1029 (468 – 1550) 551 (70 – 1740) <0.01
Treatment choice RF (n=15) TACE (n=14) p
IL-15 21.5 (7.2 – 44.6) 11.6 (0.2 – 27.8) <0.01
SDF-1a 344 (157 – 552) 511 (218 – 982) <0.01
BCLC stage A (n=17) B (n=10) p
IL-8 15 (6 – 47) 25 (10 – 54) <0.05
HGF 409 (283 – 1111) 590 (363 – 1649) <0.05
Quantification of the serum cytokines was determined by using Bio-Plex kit (Bio-Rad) in Bio-Plex array reader (Luminex, Austin, TX). Cytokines
levels were mentioned as median (min-max); statistical significance was calculated by using Student’s t-test. HCV: hepatitis C virus, TACE: transarterial
chemoembolization, RF: radiofrequency ablation, and BCLC: Barcelona Clinic Liver Cancer.
be the highest in the group of patients who had unsuccessful
treatment (NRT1), followed by the group of patients with
HCC recurrence between 1 and 6 months (NRT6), and the
lowest in the group of patients without HCC recurrence at
6 months after treatment (CR). At T0 and T1, the median
values obtained were 23.8 and 40.7 ng/ml for NRT1, 25.4
and 25.0 ng/ml for NRT6, and 6.7 and 5.3 ng/ml for CR
group. Collectively these results indicate that the level of
SCGF𝛽 could predict whether a patient would be disease-free
between 1 and 6 months after initial treatment (Figure 2).
3.3. Serum SCGF𝛽 Level as a Prognostic Value. At both T0
and T1, the predicting value of SCGF𝛽 was found to be
independent fromHCV infection and the history of previous
treatments received by the patients. Even though the level of
SCGF𝛽was slightly higher in the group of patientswhowould
receiveTACE compared to oneswithRF at T0, and inBCLCB
compared to BCLC A, it did not reach any significant values
(Figure 2). Our results had shown that the level of SCGF𝛽
was not correlated with Milan and Up-to-7 criteria. Further,
the level of SCGF𝛽 was not correlated with total volume of
the tumor. However, it might indicate that the level of SCGF𝛽
increases in accordance with the severity of the disease.
Kaplan-Meier analysis was performed to associate the
level of serum SCGF𝛽 with HCC recurrence and overall
survival (OS) (Figure 3). By using a ROC curve plotting
sensitivity/specificity, a cutoff value of 21000 pg/mL was
defined with 79% sensitivity and 80% specificity (data not
shown). From the analysis of HCC recurrence, we found that
patients with serum SCGF𝛽 higher than 21000 pg/ml had
shorter time to tumor recurrence compared to patients with
lower serum SCGF𝛽 (mean value 7.9 ± 4.4 month versus 24.8
± 5.3 month, respectively, p=0.018).
For OS analysis, the means of OS on both groups were
comparable for around 40 months (42.4 ± 8.0 versus 44.1 ±
3.9 month, respectively, p=ns). Nevertheless, the difference
on the OS probability was clearly noticed between 10 and 40
months. The analysis on RF patients alone showed a similar
trend (data not shown). This data indicated that SCGF𝛽 has
a positive prognostic value.
4. Discussions
We profiled 48 cytokines in 68 HCC sera samples in order to
select predictive biomarkers for therapy response and disease
recurrence. To our knowledge, no similar studies have been
previously reported.
As expected, in untreated patients, various cytokines
were expressed differently based on HCV positivity, previous
treatments, and the stage of the disease. In HCV-related
HCC, we observed significant differences on IP-10, IL-2Ra,
and MIG, with the highest for the IP-10 (10kDa interferon
gamma-induced protein), a proinflammatory protein. These
findings are in line with previous studies showing high
concentration of IP-10 in HCV-related liver diseases such as
acute C infection, chronic hepatitis, fibrosis, and HCC [16,
17]. IP-10 has been used to predict the response of antiviral
therapy for HCV infection [18, 19].
Weobserved that the SCGF𝛽 is one of themost significant
biomarkers in predicting early HCC recurrence after RF and
TACE.The level of SCGF𝛽was found to be the highest in the
group of patients who had unsuccessful treatment, followed
by the group of patients with early HCC recurrence (between
1 and 6months), while the lowest is in the groupwithoutHCC
recurrence at 6 months after treatment. Interestingly, this
predicting factor is independent from HCV infection, BCLC
stages, and previous treatment history. More importantly, we
found that the basal level T0 of serum SCGF𝛽 has a positive
prognostic value with HCC recurrence. Patients with high
serum SCGF𝛽 (>21000 pg/ml) has a higher probability for an
early HCC recurrence compared to those with lower level of
SCGF𝛽.
Even though we did not see a statistical difference on
the OS, a separated analysis on RF and TACE group alone
showed similar trend. The group of SCGF𝛽 level higher than
21000 pg/ml showed worse OS than the group with lower
level. Interestingly, since RF is a curative treatment, this result
indicates that, in the presence of high level of SCGF𝛽, a
curative therapy was still ineffective, thus supporting the
importance of SCGF𝛽 as a prognostic biomarker. We also
noticed that the curves began to separate only after 10months
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Figure 1: Differential levels of serum cytokines between Complete Responders (CR) and Nonresponders (NR) patients. Serum was
drawn at before treatment T0 and at 1 month after treatment T1. Cytokines concentration was expressed as median (min-max); statistical
significance was calculated by using Student’s t-test. ∗ p<0.05, ∗∗ p<0.01.
posttreatment. This pattern was caused by the maintenance
effect of treatment or reprocessing.
Until now, limited information is available regarding this
protein. The SCGF is a protein encoded by gene CLEC11A,
a member of the C-type lectin superfamily. SCGF was
selectively produced by osseous and hematopoietic stromal
cells and can mediate their proliferative activity on primitive
hematopoietic progenitor cells [20, 21]. It was also demon-
strated that beside the property of SCGF as one of the stem
cells markers, leukemic cells also required self-secreted SCGF
for their proliferation, indicating an autocrine or paracrine
SCGF regulation of hematopoietic stem/progenitor cells [22].
A recently published CoMMpass study demonstrated that, by
using an integrative network biology analysis, CLEC11A was
found to be a novel regulator and a candidate of therapeutic
target in in multiple myeloma [23].
In a very recent HCC study, a series of cytokines,
including the SCGF𝛽, IL-6, CCL2/MCP-1, CXCL1/GRO𝛼,
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Figure 2:Correlation ofSCGF𝛽 level with clinical-pathological data. SCGF𝛽 concentrationwas expressed asmedian (min-max); statistical
significance was calculated by using Student’s t-test. HCV: hepatitis C virus, TACE: transarterial chemoembolization, RF: radiofrequency
ablation, and BCLC: Barcelona Clinic Liver Cancer. ∗∗ p<0.01, ∗ ∗ ∗ p<0.001.
CXCL8/IL-8, HGF, and VEGF, were secreted from peritumor
tissue-derived fibroblasts and was shown to promote devel-
opment of HCC by recruiting CSC and maintaining their
stemness characteristic [24]. In lymphoblastic leukemia, by
using microarray analysis of 35 matched diagnosis/relapse
pairs, as well as 60 uniformly treated children at relapse, the
SCGF was found to be a gene significantly overexpressed
at relapse [25]. In chemotherapy-naive testicular germ-cell
tumor patients, elevated levels of SCGF𝛽 were associated
with worse overall survival [26]. SCGF𝛽 was also found to
be increased among different immune mediators in the sera
of the asbestos-exposed workers compared to controls [27].
In this report, consistently with other published studies, we
show that the levels of SCGF𝛽 were increased in the groups
with early HCC recurrence.
5. Conclusion
To summarize, we have demonstrated that the high level
of serum SCGF𝛽 pre- and post-treatment is associated
with HCC nonresponsiveness and early recurrence after
either RF or TACE treatment. These data indicate the
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Figure 3: Significance of basal SCGF𝛽with prognosis. Kaplan-Meier analysis of HCC recurrence and overall survival. At T0, serum SCGF𝛽
concentration higher than 21000 pg/mL is associated with a shorter recurrence time compared to concentration less than 21000 pg/mL.
significance of the growth factors of stem/progenitor cells in
HCC.
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